
Benzinga Pro data, Teva Pharmaceutical Indus (NYSE:TEVA) reported Q4 sales of $4.10 billion. Earnings fell to a loss of $153.00 million, resulting in a 150.83% decrease from last quarter. Teva Pharmaceutical Indus reached earnings of $301.00 million and sales of $3.89 billion in Q3.